{"id":"NCT00182754","sponsor":"Alliance for Clinical Trials in Oncology","briefTitle":"Octreotide in Treating Patients With Cancer-Related Malignant Ascites","officialTitle":"An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LARDepot) for Symptomatic Ascites in Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2009-09","completion":"2013-03","firstPosted":"2005-09-16","resultsPosted":"2017-04-11","lastUpdate":"2017-04-11"},"enrollment":33,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"interventions":[{"type":"DRUG","name":"octreotide acetate","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Arm I","type":"EXPERIMENTAL"},{"label":"Arm II","type":"PLACEBO_COMPARATOR"}],"summary":"RATIONALE: Octreotide may be an effective treatment for malignant ascites. It is not yet known whether octreotide is more effective than a placebo in treating malignant ascites.\n\nPURPOSE: This randomized phase III trial is studying octreotide to see how well it works compared to placebo in treating patients with cancer-related malignant ascites.","primaryOutcome":{"measure":"Median Time to Paracentesis","timeFrame":"Up to 2 years","effectByArm":[{"arm":"Arm I","deltaMin":28,"sd":null},{"arm":"Arm II","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.17"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":122,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":16},"commonTop":["Abdominal pain","Constipation","Diarrhea","Disease progression","Nausea"]}}